TABLE 2.

Pharmacokinetic parameters for lamivudine administered intravenously and orally at doses ranging from 0.5 to 10 mg/kg in 52 HIV-infected children^a

Dose level (mg/kg)	n	AUCiv (μM · h)	CL (liter/h/kg)	Vdss (liter/kg)	t1/2α (h)	t1/2β (h)	AUCpo (μM · h)	F (%)
0.5	6	5.74 ± 3.60	0.496 ± 0.242	1.04 ± 0.59	0.192 ± 0.062	2.24 ± 1.06	2.84 ± 1.04	58 ± 28
1	9	8.63 ± 1.93	0.533 ± 0.133	1.03 ± 1.07	0.221 ± 0.143	2.23 ± 2.16	6.45 ± 2.19	74 ± 18
2	12	20.6 ± 12.5	0.537 ± 0.234	0.975 ± 0.552	0.256 ± 0.173	2.16 ± 1.48	11.2 ± 5.2	63 ± 28
4	8	35.7 ± 13.7	0.536 ± 0.146	0.843 ± 0.171	0.338 ± 0.315	2.07 ± 1.47	22.5 ± 10.2	66 ± 28
6	7	55.7 ± 24.8	0.546 ± 0.206	1.03 ± 0.41	0.233 ± 0.145	3.36 ± 4.45	37.2 ± 20.7	69 ± 31
10	10	98.8 ± 35.3	0.528 ± 0.189	0.925 ± 0.333	0.144 ± 0.112	1.67 ± 0.66	61.8 ± 35.8	66 ± 26
Mean ± SD			0.531 ± 0.186	0.967 ± 0.571	0.231 ± 0.179	2.23 ± 2.09		66 ± 25

^aAUC_iv, area under the serum concentration-time curve for the intravenous dose; Vd_ss, volume of distribution at steady state; AUC_po, area under the serum concentration-time curve for the oral dose; F, bioavailability of the oral dose.